Multisegmental spondylitis due to Tropheryma whipplei: Case report by Spoerl, David et al.
BioMed  Central
Page 1 of 3
(page number not for citation purposes)
Orphanet Journal of Rare Diseases
Open Access Case Report
Multisegmental spondylitis due to Tropheryma whipplei: Case report
David Spoerl, Diego Bär, Julian Cooper, Thomas Vogt, Alan Tyndall and 
Ulrich A Walker*
Address: Department of Rheumatology, University of Basel, Felix Platter Spital, Basel, Switzerland
Email: David Spoerl - spoerld@uhbs.ch; Diego Bär - diegobaer@gmx.ch; Julian Cooper - julian.cooper@me.com; 
Thomas Vogt - thomas.vogt@fps-basel.ch; Alan Tyndall - alan.tyndall@fps-basel.ch; Ulrich A Walker* - ulrich.walker@fps-basel.ch
* Corresponding author    
Abstract
We report a patient who presented with inflammatory back pain due to multisegmental spondylitis.
Following a vertebral biopsy which failed to detect an infectious organism, the patient was treated
with etanercept, a tumor necrosis factor (TNF)-α inhibitor, for suspected undifferentiated
spondyloarthritis. The back pain worsened and the spondylitic lesions increased. Only in a vertebral
rebiopsy with polymerase chain reaction (PCR) amplification of Tropheryma whipplei, the causative
agent of Whipple's disease was identified. Tropheryma whipplei should be considered as a cause of
spondylitis even with multisegmental involvement and in the absence of gastrointestinal symptoms.
In this clinical setting, routine PCR for Tropheryma whipplei from vertebral biopsies is
recommended.
Background
Low back pain is commonly conceptualised and managed
as being either mechanical or inflammatory in nature. The
inflammatory origin of low back pain can be sensitively
detected by magnetic resonance imaging (MRI) [1]. Fre-
quently patients with spondylitis suffer from "autoim-
mune" spondyloarthritis, a group of disorders that
includes ankylosing spondylitis, reactive arthritis, and the
spondylitis that may accompany psoriasis and inflamma-
tory bowel diseases. All these forms of spondylitis are
amenable to treatment with TNF-α blockers. Infection
should be ruled out in atypical cases by searching for foci,
blood culture and eventually vertebral biopsy. In contrast
to the multisegmental spinal involvement typical of the
"autoimmune" spondyloarthritis group of disorders, it is
unusual for infectious agents to manifest with spondylitis
on multiple levels in the lumbar spine [2]. Staphylococcus
aureus is the most common organism involved in spinal
infections and is thought to hematogenously spread
through the paravertebral collateral arteria into the verte-
bral bone marrow [3].
Whipple's disease is a rare, multisystemic infection caused
by  Tropheryma whipplei. Symptoms usually include
diarrhea, weight loss, malabsorption and migratory oligo-
or polyarthritis. The arthropathy usually precedes gas-
trointestinal symptoms by years. Diagnosis is generally
made by small bowel biopsy or PCR amplification from
the biopsy specimen [4].
We report the first case of multisegemental spondylitis
due to infection with Tropheryma whipplei. Following a first
negative result of a vertebral biopsy in which PCR ampli-
fication has not been performed, the patient was errone-
ously treated with a TNF-α inhibitor for suspected
undifferentiated spondyloarthritis.
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Case presentation
In the year 2002, a 64 year old man presented with a 5
year history of inflammatory back pain and repeated,
bone-scan confirmed, transient flares of arthritis involv-
ing one proximal interphalangeal, both tibiotalar, and tar-
sometarsal joints. His physical examination was
otherwise normal. Laboratory tests revealed inflamma-
tion (erythrocyte sedimentation rate (ESR) 34 mm/h, C-
reactive protein (CRP) 164 g/L). A contrast-enhanced, T1
weighted, fat saturated MRI scan of the spine showed con-
trast enhancing lesions in the first (L1) and second (L2) as
well as fourth (L4) and fifth (L5) lumbar vertebra which
spared the intervertebral discs (Fig 1A). Biopsy of the sec-
ond lumbar vertebral (L2) lesion failed to show inflam-
mation; cultures were negative. Chest X-ray, abdominal
ultrasonography, transesophageal echocardiography, gas-
troduodenoscopy, and colonoscopy were normal, as were
blood cultures and searches for mycobacteria and HIV. He
was then started on low-dose corticosteroids and meth-
otrexate had been added to the regimen in August 2004.
After disease progression, methotrexate had been replaced
by anti-TNF-α treatment with etanercept in August 2005
for suspected undifferentiated spondyloarthritis. Conse-
quently, lethargy, night-sweats, and weight loss (10 kg in
6 months) developed. No other gastrointestinal symp-
toms existed. The back pain and inflammation (ESR 60
mm/h and CRP 860 g/L) worsened. A control MRI (Fig
1B) showed erosive disease. A rebiopsy of the second lum-
bar vertebra was performed. PCR from the vertebral
biopsy amplified a DNA product, which was confirmed by
sequencing to originate from Tropheryma whipplei. Retro-
spectively, the same pathogen was detected by PCR in the
gastric biopsy from the year 2002. No PCR amplification
had been carried out in the cerebrospinal fluid. Coinfec-
tion with Giardia lamblia was diagnosed by repeat gas-
troduodenoscopy which at this time also revealed the
typical periodic acid-Schiff (PAS)-positive macrophages in
the duodenal mucosa.
The immunosuppressive treatment was stopped and
sequential treatment of Tropheryma whipplei with ceftri-
axon and cotrimoxazol was initiated in February 2006.
Giardia lamblia was treated with metronidazol. After 12
months of treatment, the patient was in clinical remission
with marked improvement of the spinal lesions (Fig 1C).
In July 2007, cotrimoxazol was switched to doxycyclin
plus hydroxychloroquine because the laboratory markers
of inflammation were still mildly elevated (CRP 5.5 mg/l,
ESR 26 mm/h). In August 2008 there were no clinical or
serological signs of inflammation, another control MRI
showed no signs of activity. Treatment was discontinued
in October 2008 due to doxycyclin induced phototoxic
skin eruptions [5]. At his last follow-up in February 2009,
there was no sign of relapse.
Conclusion
Spondylitis is a rare manifestation of Whipple's disease.
Multisegmental involvement has to our knowledge not
been reported before. The first symptom of Whipple's dis-
ease usually is a polyarthritis. Typically the diagnosis of
the underlying infection is delayed for several years [6].
The physician and rheumatologist should be aware of this
rare differential diagnosis of arthritis and spondyloarthri-
tis. Erosive intervertebral disease and a L4/5 location of
inflammatory lesions are not typical for primary spondy-
loarthritis. An accelerated progression and onset of new
gastrointestinal symptoms has been described in a few
cases of Whipple's disease treated with non-biologic and
biologic immunosuppressants [7]. A septic, life-threaten-
ing disease course has been reported under immunosup-
pression [8]. Tropheryma whipplei should be considered
even in the absence of gastrointestinal symptoms; there-
fore routine PCR from vertebral biopsies is recommended
[9]. Typically, the diagnosis is made by PAS staining of
small-bowel-biopsy specimens and occasionally also
other tissues, which on light microscopy show magenta-
stained inclusions within macrophages. Immunohisto-
chemistry may provide greater sensitivity and specificity
than does PAS staining but is not widely available. Our
case suggests that PCR from gastrointestinal sources can
be more sensitive than the demonstration of PAS-positive
MRI alterations during follow-up Figure 1
MRI alterations during follow-up. Contrast-enhanced, 
T1 weighted, fat saturated MRI demonstrating progression of 
two spondylitic lesions with the onset of clear erosions in the 
L1/L2 segment during treatment with etanercept, a TNF-α 
blocking agent between years 2002 and 2005. After cessation 
of the TNF-α blocker and initiation of antibiotic treatment, 
the multisegmental spondylitis regressed (year 2006).Publish with BioMed Central    and   every 
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macrophages in histopathology. Last but not least, the
case provides further support for an association between
Whipple's disease and Giardia lamblia infection [10]. The
pathogenesis of this coinfection is unclear but may be pro-
moted by a common immune defect, a common source of
infection, or the circumstance that infection with one
organism may predispose to infection with the other [10].
If untreated, Whipple's disease is invariably fatal. An effec-
tive antibiotic regimen consists of ceftriaxone (2 g daily)
for 2 weeks, followed by cotrimoxazole (160 mg of tri-
methoprim and 800 mg of sulfamethoxazole twice per
day) for 1 to 2 years. In case of an unsatisfactory clinical
response or a relapse, doxycycline (200 mg/day) plus
hydroxychloroquine (200 mg three times per day), an
alkalinizing agent which decreases the viability of Troph-
eryma whipplei in phagosomes, is recommended [10]. Typ-
ical histopathological findings in duodenal biopsies can
however persist for several years after successful antibiotic
therapy [11].
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